Ontology highlight
ABSTRACT:
SUBMITTER: Johnson DB
PROVIDER: S-EPMC7165046 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
Johnson Douglas B DB Zhao Fengmin F Noel Marcus M Riely Gregory J GJ Mitchell Edith P EP Wright John J JJ Chen Helen X HX Gray Robert J RJ Li Shuli S McShane Lisa M LM Rubinstein Larry V LV Patton David D Williams P Mickey PM Hamilton Stanly R SR Conley Barbara A BA Arteaga Carlos L CL Harris Lyndsay N LN O'Dwyer Peter J PJ Chen Alice P AP Flaherty Keith T KT
Clinical cancer research : an official journal of the American Association for Cancer Research 20200110 8
<h4>Purpose</h4>Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with <i>BRAF</i> mutations outside the V600 locus, and in <i>BRAF</i> fusions. Thus, Subprotocol R of the NCI-MATCH study tested the MEK inhibitor trametinib in this population.<h4>Patients and methods</h4>The NCI-MATCH study performed genomic profiling on tumor samples from patients with solid tumors and lymphomas progressing on standard therapies or with no standard tre ...[more]